Praxis Precision Medicines, Inc.(PRAX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
PRAX Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Praxis Precision Medicines, Inc. (PRAX), a Healthcare sector company. PRAX is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), Praxis Precision Medicines, Inc. reports net income of $-83.7M, free cash flow of $-77.8M. Top institutional holders of PRAX by reported 13-F value include Jupiter Topco, FMR, BlackRock, based on the most recent SEC filings. PRAX trades on the Nasdaq exchange and files with the SEC under CIK 1689548. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PRAX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Praxis Precision Medicines, Inc. directly from SEC EDGAR.
Net Income
Q2 2026
$-83.7M
Free Cash Flow
Q2 2026
$-77.8M
ROIC
Q2 2026
-28.9%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
-100.0% YoYNet Income
-65.9% YoYOperating Income
-63.0% YoYEPS (Diluted)
-32.0% YoYTotal Assets
+94.1% YoYOp. Cash Flow
-89.0% YoYFree Cash Flow
-89.1% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 -100.0% | $8.6M +249.5% | $2.4M | $0.00 | — | — |
| Net Income | $-303.3M -65.9% | $-182.8M -48.3% | $-123.3M +42.4% | $-214.0M -28.1% | $-167.1M -170.2% | $-61.8M |
| Operating Income | $-326.2M -63.0% | $-200.2M -58.4% | $-126.4M +41.2% | $-215.0M -28.5% | $-167.3M -170.0% | $-62.0M |
| EPS (Diluted) | $-13.48 -32.0% | $-10.21 +45.4% | $-18.69 +73.2% | $-69.65 -1667.8% | $-3.94 +49.9% | $-7.86 |
| Total Assets | $937.9M +94.1% | $483.1M +449.3% | $87.9M -23.6% | $115.1M -60.7% | $292.7M -3.4% | $303.2M |
| Operating Cash Flow | $-249.1M -89.0% | $-131.8M -18.6% | $-111.1M +39.9% | $-185.0M -48.6% | $-124.6M -136.7% | $-52.6M |
| Free Cash Flow | $-249.1M -89.1% | $-131.8M -18.5% | $-111.2M +40.1% | $-185.5M -47.7% | $-125.6M -138.7% | $-52.6M |
Get alerted when PRAX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Praxis Precision Medicines, Inc. including:
Top Institutional Holders of PRAX
Jupiter Topco LLC
$1.1B3,421,374 shFMR LLC
$775.7M2,316,907 shBlackRock, Inc.
$767.5M2,292,585 shPERCEPTIVE ADVISORS LLC
$681.6M2,035,986 shBAKER BROS. ADVISORS LP
$587.0M1,753,198 shOrbis Allan Gray Ltd
$512.2M1,529,788 shVANGUARD PORTFOLIO MANAGEMENT LLC
$447.0M1,335,185 shVANGUARD CAPITAL MANAGEMENT LLC
$413.6M1,235,299 shSTATE STREET CORP
$343.7M1,026,443 shADAGE CAPITAL PARTNERS GP, L.L.C.
$340.0M1,015,480 sh
| Fund | Value | Shares |
|---|---|---|
| Jupiter Topco LLC | $1.1B | 3,421,374 |
| FMR LLC | $775.7M | 2,316,907 |
| BlackRock, Inc. | $767.5M | 2,292,585 |
| PERCEPTIVE ADVISORS LLC | $681.6M | 2,035,986 |
| BAKER BROS. ADVISORS LP | $587.0M | 1,753,198 |
| Orbis Allan Gray Ltd | $512.2M | 1,529,788 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $447.0M | 1,335,185 |
| VANGUARD CAPITAL MANAGEMENT LLC | $413.6M | 1,235,299 |
| STATE STREET CORP | $343.7M | 1,026,443 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $340.0M | 1,015,480 |
More Healthcare Companies
View all Healthcare →Put PRAX on your watchlist
Track score changes the day Praxis Precision Medicines, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is PRAX a good stock to buy?
13F Pro's AI-powered analysis of Praxis Precision Medicines, Inc. (PRAX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PRAX are available on the PRAX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. PRAX is classified as a mid company.
Which hedge funds own PRAX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PRAX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Praxis Precision Medicines, Inc.'s investment landscape.